Article Text

other Versions

PDF
Anakinra treatment of SAPHO syndrome: short-term results of an open study
  1. Daniel Wendling1,
  2. Clément Prati1,
  3. François Aubin2
  1. 1Université de Franche-Comté et Service de Rhumatologie, Centre Hospitalier Universitaire de Besançon, France
  2. 2Université de Franche-Comté et Service de Dermatologie, Centre Hospitalier Universitaire de Besançon, France
  1. Correspondence to Professor Daniel Wendling, Université de Franche-Comté et Service de Rhumatologie, Centre Hospitalier Universitaire de Besançon, Besancon 25030, France; dwendling{at}chu-besancon.fr

Statistics from Altmetric.com

SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome comprises many features, but has no specific treatment.1 2 According to the target symptom (synovitis, skin, bone) non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), bisphosphonates3 and tumour necrosis factor (TNF) blockers4 may be proposed, but with variable results. Some patients do not exhibit improvement of symptoms despite use of several, sometimes combined, lines of treatment. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist has recently been described5 under the name DIRA. It associates sterile multifocal osteomyelitis, periostitis and pustulosis, which looks like SAPHO, with good response to anakinra, an interleukin 1 (IL-1) receptor antagonist. We describe the …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.